220362-31-2

Usage

Uses

Used in Pharmaceutical Research and Development:
Benzeneethanamine, 3,4-difluoro(9CI) is utilized as a building block for the synthesis of various drugs and biologically active molecules. Its unique structure and properties contribute to the development of new pharmaceuticals and therapeutic agents, enhancing their efficacy and selectivity.
Used in Drug Synthesis:
In the pharmaceutical industry, Benzeneethanamine, 3,4-difluoro(9CI) serves as a key intermediate in the synthesis of a wide range of drugs. Its presence in the molecular structure can influence the pharmacokinetics, pharmacodynamics, and overall therapeutic potential of the resulting compounds.
Used in Medicinal Chemistry:
Benzeneethanamine, 3,4-difluoro(9CI) is employed in medicinal chemistry for the design and optimization of drug candidates. Its incorporation into molecular frameworks can modulate the physicochemical properties, such as lipophilicity, solubility, and stability, which are crucial for drug development.
It is important to handle Benzeneethanamine, 3,4-difluoro(9CI) with care, as it may pose health and environmental hazards if not properly managed. Proper safety measures and disposal methods should be followed to minimize any potential risks associated with its use.

Upstream product

• 1025692-47-0 1-[(E)-2-nitroethenyl]-3,4-difluorobenzene 
• 885068-38-2 1,2-difluoro-4-(2-nitro-vinyl)-benzene 
• 658-99-1 (3,4-difluorophenyl)acetonitrile 

Downstream Products

• 875305-26-3 2-(3,4-difluoro-phenyl)-ethyl-amine hydrochloride 
• 885068-39-3 (6-chloro-2-methoxy-pyrimidin-4-yl)-[2-(3,4-difluoro-phenyl)-ethyl]-amine 
• 1060788-22-8 (S)-1-(4-methanesulfonamidophenoxy)-3-(3,4-difluorophenylethylamino)-2-propanol 
• 885068-40-6 3-{6-[2-(3,4-difluoro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenol 
• 1292286-14-6 C₂₆H₃₀FN₃O₅ 
• 1292286-17-9 C₂₇H₃₄FN₃O₅S 

Relevant academic research and scientific papers

17a-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

Indole, indazole and indoline derivatives as CETP inhibitors

The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.